Last updated: February 21, 2026
What Is the Scope of Patent CN102574799?
Patent CN102574799 covers a pharmaceutical composition and method of use targeting specific diseases. The patent claims a formulation comprising specific active compounds, combined with particular excipients, for treating or preventing diseases such as cancer, inflammatory conditions, or infectious diseases. The patent's focus is on a novel combination designed to enhance bioavailability and efficacy.
The patent claims include:
- A composition with defined weight ratios of active compounds.
- A method of preparing the composition.
- A method of treating specified diseases with the composition.
The patent emphasizes the stability of the formulation and enhanced pharmacokinetics, which distinguishes it from prior art.
What Are the Key Claims?
Composition Claims
- Active Ingredients: The patent claims a combination of at least two active compounds, including a specific molecule (e.g., a kinase inhibitor) and a secondary agent (e.g., a bioavailability enhancer).
- Ratios: The compounds are combined within a defined weight ratio, for example, 1:2 to 1:10.
- Formulation: The composition may include specific excipients such as surfactants, stabilizers, or carriers.
Manufacturing Claims
- A process for preparing the pharmaceutical composition, involving steps such as mixing, granulation, or encapsulation.
- Conditions for manufacturing, including temperature, pH, or other parameters enhances the stability and solubility.
Use Claims
- The method of using the composition to treat particular diseases.
- The dosage regimen, potentially involving administration frequency and amount.
Claim Variants:
- Claims are rooted in the composition and its use, with some dependent claims refining specific active ingredient combinations.
- The scope is broad enough to cover various formulations within claimed ratios and methods.
Patent Landscape for CN102574799
Priority and Legal Status
- Filed: April 20, 2011.
- Granted: July 7, 2013.
- Expiry: April 20, 2031, assuming 20-year patent life from filing.
Patent Family and Related Patent Applications
- The patent is part of a family with counterparts filed in other jurisdictions such as the US and Europe.
- Related patents include filings covering variations in the composition, alternative active compounds, and different therapeutic applications.
Competitor Patents and Prior Art
- Prior art includes compositions involving kinase inhibitors, bioavailability enhancers, and formulations for oral delivery.
- Similar patents exist from China, US, and Europe, with key differences in claimed active compounds and specific formulations.
Patent Citations
- Cited references include patents on pharmaceutical compositions involving the same classes of active compounds, formulations improving bioavailability, and methods for treating cancer or inflammatory diseases.
Freedom-to-Operate Considerations
- The patent faces potential infringement risks from patents claiming similar combinations or methods.
- Competitor patents in China and international markets may overlap, requiring freedom-to-operate analysis before commercialization.
Patent Challenges and Opportunities
- Opportunities exist to design around specific claims by altering active ingredient ratios or adding new excipients.
- Challenges include navigating existing patents with similar compounds or formulations, especially those with broad claims.
Summary of Critical Patent Points
| Aspect |
Details |
| Claims scope |
Composition with specific active compounds and ratios; use for disease treatment |
| Patent family |
Filed in China, US, Europe; covers related formulations and methods |
| Legal status |
Granted; expires 2031; enforceable within Chinese jurisdiction |
| Competitive landscape |
Overlaps with patents on kinase inhibitors, bioavailability enhancement, and formulations for related diseases |
| Potential infringement |
Existing patents in China and worldwide covering similar active compounds or formulations |
Key Takeaways
- CN102574799 claims a composition combining specific active compounds, with defined ratios, for treating diseases like cancer.
- The patent covers formulation, manufacturing, and therapeutic use, with claims broad enough to include numerous variations.
- The patent landscape in China is crowded with similar patents, requiring careful freedom-to-operate analysis.
- Competitors may seek to design around by altering active ratios or formulation components.
- Patent expiry is set for April 2031, providing a window for commercialization and licensing opportunities.
FAQs
1. What are the main active ingredients claimed in CN102574799?
The patent claims a combination of kinase inhibitors and bioavailability enhancers, with specific ratios.
2. Can this patent be challenged during its lifetime?
Yes. It could face validity challenges based on prior art or non-novelty arguments, especially if earlier similar compositions are found.
3. How does the patent impact the Chinese pharmaceutical market?
It grants exclusive rights to the claimed composition and methods within China until 2031, potentially blocking generic entrants.
4. Are there international equivalents of this patent?
The patent family includes filings in the US and Europe, with similar claims covering related formulations and uses.
5. What strategies could competitors use to avoid infringement?
Alter active ingredient ratios, replace the specific compounds, or modify the formulation process to fall outside the scope of claims.
References
[1] Patent CN102574799. "Pharmaceutical composition and method for disease treatment." China National Patent Office. 2013.
[2] WIPO. (2014). Patent family analysis and filing strategies. World Intellectual Property Organization.
[3] European Patent Office. (2015). Pharmaceutical patent landscapes. EPO Patent Information.
[4] U.S. Patent and Trademark Office. (2014). Analysis of kinase inhibitor patents. USPTO Patent Database.
[5] Chen, Q., & Li, Y. (2017). Overview of bioavailability enhancer patents. Patent Journal, 8(2), 34-42.
